About Cognition Therapeutics, Inc.
https://www.cogrx.comCognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
CEO
Lisa Ricciardi
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BIOS CAPITAL MANAGEMENT, LP
Shares:6M
Value:$8.52M
DAVENPORT & CO LLC
Shares:2.69M
Value:$3.82M
VANGUARD GROUP INC
Shares:2.68M
Value:$3.81M
Summary
Showing Top 3 of 80
About Cognition Therapeutics, Inc.
https://www.cogrx.comCognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $6.31M ▼ | $-4.93M ▲ | 0% | $-0.06 ▲ | $-4.87M ▲ |
| Q2-2025 | $0 | $13.98M ▲ | $-6.73M ▲ | 0% | $-0.11 ▲ | $-6.67M ▲ |
| Q1-2025 | $0 | $13.78M ▲ | $-8.48M ▼ | 0% | $-0.14 ▲ | $-8.43M ▼ |
| Q4-2024 | $0 | $10.72M ▼ | $-7.84M ▲ | 0% | $-0.17 ▲ | $-7.77M ▲ |
| Q3-2024 | $0 | $14.46M | $-9.94M | 0% | $-0.25 | $-9.86M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $39.82M ▲ | $43.4M ▲ | $6.87M ▼ | $36.53M ▲ |
| Q2-2025 | $10.74M ▼ | $19.62M ▼ | $12.59M ▲ | $7.03M ▼ |
| Q1-2025 | $16.43M ▼ | $23.5M ▼ | $11.23M ▼ | $12.27M ▼ |
| Q4-2024 | $25.01M ▲ | $30.23M ▲ | $11.48M ▼ | $18.75M ▲ |
| Q3-2024 | $22.01M | $27.58M | $13.1M | $14.48M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-4.93M ▲ | $-5.65M ▼ | $0 | $33.92M ▲ | $28.27M ▲ | $-5.65M ▼ |
| Q2-2025 | $-6.73M ▲ | $-5.62M ▲ | $0 | $752K ▼ | $-4.87M ▲ | $-5.62M ▲ |
| Q1-2025 | $-8.48M ▼ | $-9.88M ▼ | $0 ▲ | $1.3M ▼ | $-8.58M ▼ | $-9.88M ▼ |
| Q4-2024 | $-7.84M ▲ | $-8.38M ▼ | $-1K ▼ | $11.38M ▲ | $3M ▲ | $-8.38M ▼ |
| Q3-2024 | $-9.94M | $-6.85M | $0 | $329K | $-6.52M | $-6.85M |
CEO
Lisa Ricciardi
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BIOS CAPITAL MANAGEMENT, LP
Shares:6M
Value:$8.52M
DAVENPORT & CO LLC
Shares:2.69M
Value:$3.82M
VANGUARD GROUP INC
Shares:2.68M
Value:$3.81M
Summary
Showing Top 3 of 80